display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
mNSCLC - L2 - all populationmNSCLC - L2 - EGFR mutantmNSCLC - L2 - PDL1 positivenon squamous - mNSCLC - L2 - all populationsquamous - mNSCLC - L2 - all population
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone OAK ... POPLAR OAK ...
avelumab based treatment
avelumab alone JAVELIN Lung 200 ... JAVELIN Lung 200 ...
durvalumab based treatment
durvalumab alone ARCTIC ...
durvalumab plus osimertinib CAURAL ...
nivolumab based treatment
nivolumab alone CheckMate 078 CheckMate 057 CheckMate 017
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg) KEYNOTE-010 ... KEYNOTE-010 ...
pembrolizumab (2mg/kg) KEYNOTE-010 ... KEYNOTE-010 ...
Tislelizumab RATIONALE 303

Study type: